The science and practice of medication-assisted treatments for opioid dependence

Substance Use and Misuse

Volumn 47, Issue 8-9, 2012, Pages 1026-1040

  Pecoraro, Anna ^a,b   Ma, Michelle ^a,b,c   Woody, George E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Delaware Valley Node   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

buprenorphine; diamorphine; heroin; history; methadone; opioid addiction

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HUMAN; METHODOLOGY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PEER GROUP;

ANALGESICS, OPIOID; ATTITUDE OF HEALTH PERSONNEL; BUPRENORPHINE; EVIDENCE-BASED MEDICINE; HEALTH PERSONNEL; HEROIN; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PEER GROUP;

EID: 84862548274     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2012.663292     Document Type: Review

References (175)

1. Abbott, P. J.,Weller, S. B., Delaney, H. D., & Moore, B. A. (1998). Community reinforcement approach in the treatment of opiate addicts. American Journal of Drug and Alcohol Abuse, 24(1), 17-30. (Pubitemid 28101088)
2. Abouyanni, G., Stevens, L. J., Harris, M. F., Wickes, W. A., Ramakrishna, S. S., Ta, E., et al. (2000). GP attitudes to managing drug- and alcohol-dependent patients: A reluctant role. Drug and Alcohol Review, 19(2), 165-170.
3. Acker, C. J. (1997). The early years of the PHS Narcotic Hospital at Lexington, Kentucky. Public Health Reports, 112, 245-247.
4. Amato, L., Davoli, M., Minozzi, S., Ali, R., & Ferri, M. (2005). Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, 3, Art. No. CD003409; doi: 10.1002/14651858. CD003409.pub3.
5. Amato, L.,Minozzi, S., Davoli, M., Vecchi, S., Ferri,M., &Mayet, S. (2008a). Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews, 4, Art. No. CD005031; doi: 10.1002/14651858.CD005031.pub3.
6. Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M. M., & Mayet, S. (2008b). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews, 4, Art. No. CD005031; doi:10.1002/14651858.CD005031.pub3.
7. Andrews, S., Sorensen, J. L., Guydish, J., Delucchi, K., & Greenberg, B. (2006). Knowledge and attitudes about methadone maintenance among staff working in a therapeutic community. Journal of Maintenance in the Addictions, 3(1), 47-59. (Pubitemid 44157105)
8. Angarola, R. T. (1990). National and international regulation of opioid drugs: Purpose, structures, benefits and risks. Journal of Pain and Symptom Management, 5(1 suppl.), S6-S11. (Pubitemid 20156194)
9. Araǵon-Poce, F., Martinez-Fernandez, E., Marquez-Espinos, C., Perez, A., Mora, R., & Torres, L. M. (2002). History of opium. International Congress Series, 1242, 19-21.
10. ASAM (American Society of Addiction Medicine). 2006 ASAM public policy statement on methadone treatment of addiction Chevy Chase, MD: Author.
11. Avants, S. K., Margolin, A., Usubiaga, M. H., & Doebrick, C. (2004). Targeting HIV-related outcomes with intravenous drug users maintained on methadone: A randomized clinical trial of a harm reduction group therapy. Journal of Substance Abuse Treatment, 26(2), 67-78. (Pubitemid 38402015)
12. Bacon, S. D. (2008). The classic Temperance Movement of the USA: Impact today on attitudes, action and research. British Journal of Addiction to Alcohol & Other Drugs, 62(1-2), 5-18.
13. Ball, J. C.,&Ross, A. (1991). The effectiveness of methadone maintenance treatment. New York: Springer-Verlag.
14. Baumohl, J., & White, W. (2003). Treatment institutions. In J. Blocker & I. Tyrell (Eds.), Alcohol and temperance in modern history (pp. 619-624). Santa Barbara, CA: ABC-CLIO.
15. Bell, J., Chan, J., & Kuk, A. (1995). Investigating the influence of treatment philosophy on outcome of methadone maintenance. Addiction, 90(6), 823-830.
16. Bendtsen, P., & Akerlind, I. (1999). Changes in attitudes and practices in primary health care with regard to early intervention for problem drinkers. Alcohol and Alcoholism, 34(5), 795-800. (Pubitemid 29467072)
17. Berridge, V. (1982). Part I. Historical perspectives: Opiate use in England, 1800-1926. Annals of the New York Academy of Sciences, 398, 1-11.
18. Bickel, W. K., Amass, L., Higgins, S. T., Badger, G. J., & Esch, R. A. (1997). Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology, 65(5), 803-810. (Pubitemid 27439072)
19. Blumberg, H., & Dayton, H. B. (1973). Naloxone and related compounds. In H. W. Kosterlitz, J. O. Collier & J. Villarreal (Eds.), Agonist and antagonist actions of narcotic analgesic drugs (pp. 110-119). New York: Macmillan.
20. Brown, B. S., Jansen, D. R., & Bass, U. F. (1974). Staff attitudes and conflict regarding the use of methadone in the treatment of heroin addiction. American Journal of Psychiatry, 131, 215-219.
21. Brownstein,M. J. (1993).Abrief history of opiates, opioid peptides, and opioid receptors. Proceedings of the National Academy of Sciences, 90(12), 5391-5393. (Pubitemid 23176165)
22. Caplehorn, J. R. M., & Bell, J. (1991). Methadone dosage and retention of patients in maintenance treatment. Medical Journal of Australia, 154(3), 195-199.
23. Caplehorn, J. R. M., Bell, J., Klein, D. G., & Gebski, V. J. (1993). Retention in methadone maintenance and addicts' risk of death. Addiction, 89(2), 203-207.
24. Caplehorn, J. R. M., Hartel, D. M., & Irwig, L. (1997). Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. Substance Use & Misuse, 32(4), 399-413. (Pubitemid 27150052)
25. Caplehorn, J. R. M., lrwig, L., & Saunders, J. B. (1996). Physicians'attitudes and retention of patients in their methadone maintenance programs. Substance Use & Misuse, 31(6), 663-667.
26. Caplehorn, J. R. M., Lumley, T. S., & lrwig, L. (1998). Staff attitudes and retention of patients in methadone maintenance programs. Drug and Alcohol Dependence, 52(1), 57-61. (Pubitemid 28448703)
27. Caplehorn, J. R. M., Lumley, T. S., Irwig, L., & Saunders, J. B. (1998). Changing attitudes and beliefs of staff working in methadone maintenance programs. Australian and New Zealand Journal of Public Health, 22(4), 505-508. (Pubitemid 28339695)
28. Carise, D. A., McLellan, A. T., & Gifford, L. S. (2000). Development of a 'treatment program' descriptor: The addiction treatment inventory. Substance Use & Misuse, 35(12-14), 1797-1818. (Pubitemid 32004728)
29. Carise, D. A., McLellan, A. T., Gifford, L. S., & Kleber, H. D. (1999). Developing a national addiction treatment information system: An introduction to the drug evaluation network system. Journal of Substance Abuse Treatment, 17(1-2), 67-77. (Pubitemid 29354123)
30. Carrẽno, J. E., Alvarez, C. E., San Narciso, G. I., Bascaran, M. T., D́iaz, M., & Bobes, J. (2003). Maintenance treatment with depot opioid antagonists in subcutaneous implants: An alternative in the treatment of opioid dependence. Addiction Biology, 8(4), 429-438. (Pubitemid 38102049)
31. Carrieri, M. P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & Woody, G. E. (2006). Buprenorphine use: The international experience. Clinical Infectious Diseases, 43(S4), S197-S215. (Pubitemid 44901888)
32. Carroll, K. M., Ball S. A., Nich, C., O'Connor, P. G., Eagan, D. A., Frankforter, T. L., et al. (2001). Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: Efficacy of contingency management and significant other involvement. Archives of General Psychiatry, 58(8), 755-761. (Pubitemid 32717799)
33. Castells, X., Kosten, T. R., Capell̀a, D., Vidal, X., Colom, J., & Casas, M. (2009). Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. American Journal of Drug and Alcohol Abuse, 35(5), 339-349.
34. Chander, G., Himelhoch, S., & Moore, R. D. (2006). Substance abuse and psychiatric disorders in HIV-positive patients: Epidemiology and impact on antiretroviral therapy. Drugs, 66(6), 769-789. (Pubitemid 43765224)
35. Chappel, J. N., Veach, T. L., & Krug, R. S. (1985). The substance abuse attitude survey: An instrument for measuring attitudes. Journal of Studies on Alcohol, 46(1), 48-52. (Pubitemid 15171796)
36. Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., et al. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry, 63(2), 210-218. (Pubitemid 43213883)
37. CSAT Buprenorphine Information Center. (2010). Frequently asked questions about buprenorphine and the Drug Addiction Treatment Act of 2000 (DATA 2000). Retrieved from http://buprenorphine.samhsa.gov/faq.html#A11
38. Dave, D., & Mukerjee, S. (2011). Mental health parity legislation, cost-sharing and substance abuse treatment admissions. Health Economics, 20(2), 161-183.
39. Davenport-Hines, R. (2004). The pursuit of oblivion: A global history of narcotics. New York: W.W. Norton & Company.
40. Dennis, M. L., & Scott, C. K. (2007). Managing addiction as a chronic condition. Addiction Science and Clinical Practice, 4(1), 45-55.
41. DeQuincey, T. (1821). Confessions of an opium eater. London Magazine, September and October.
42. Dole, V. P., & Nyswander, M. E. (1965). A medical treatment for diacetylmorphine (Heroin) addiction: A clinical trial with methadone hydrochloride. Journal of the American Medical Association, 193(8), 646-650.
43. Dole, V. P., & Nyswander, M. E. (1967) Heroin addiction: A metabolic disease. Archives of Internal Medicine, 120(1),19-24.
44. Dole, V. P., Nyswander, M. E., & Kreek, M. J. (1966). Narcotic blockade. Archives of Internal Medicine, 118(4), 304-309.
45. Durrant, R., & Thakker, J. (2003). Substance use and abuse: Cultural and historical perspectives. Thousand Oaks, CA: Sage.
46. Dwarakanath, S. C. (1965). Use of opium and cannabis in the traditional systems of medicine in India. Bulletin on Narcotics, 17(1), 15-19.
47. Eissenberg, T., Greenwald, M. K., Johnson, R. E., Liebson, I. A., Bigelow, G. E., & Stitzer, M. L. (1996). Buprenorphine's physical dependence potential: Antagonist precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics, 276(2), 449-459.
48. Eissenberg, T., Johnson, R. E., Bigelow, G. E., Walsh, S. L., Liebson, I. A., Strain, E. C., et al. (1997). Controlled opioid withdrawal evaluation during 72 hour dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence, 45(1-2), 81-91. (Pubitemid 27246409)
49. Emmanuelli, J., & Desenclos, J. C. (2005). Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction, 100(11), 1690-1700. (Pubitemid 41626829)
50. Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003). Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews, 3, Art. No. CD002208. doi: 10.1002/14651858. CD002208.
51. Federal Bureau of Narcotics. (1955). Narcotics clinics in the United States. Washington, DC: U.S. Government Printing Office.
52. Forman, R. F., Bovasso, G., & Woody, G. (2001). Staff beliefs about addiction treatment. Journal of Substance Abuse Treatment, 21(1), 1-9. (Pubitemid 32757235)
53. Fort, J. (1965). Giver of delight or liberator of sin: Drug use and 'addiction' in Asia. Bulletin on Narcotics, 17(3), 1-11.
54. Foster, J., Brewer, C., & Steele, T. (2003). Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addiction Biology, 8(2), 211-217. (Pubitemid 36859662)
55. Friedmann, P. D., Lemon, S. C., Stein, M. D., & D'Aunno, T. A. (2003). Accessibility of addiction treatment: Results from a national survey of outpatient substance abuse treatment organizations. Health Services Research, 38(3), 887-903. (Pubitemid 36682491)
56. Galea, S., Worthington, N., Piper, T. M., Nandi, V. V., Curtis, M., & Rosenthal, D. M. (2006). Provision of naloxone to injection drug users as an overdose prevention strategy: Early evidence from a pilot study in New York City. Addictive Behaviors, 31(5), 907-912.
57. Gerlach, R., & Caplehorn, J. R. M. (1999). Attitudes and beliefs of doctors prescribingmethadone to addicts in theWestfalen-Lippe region of Germany. Drug and Alcohol Review, 18(2), 163-170.
58. Giannetti, V. J., Sieppert, J. D., & Holosko, M. J. (2002). Attitudes and knowledge concerning alcohol abuse: Curriculum implications. Journal of Health and Social Policy, 15(1), 45-58. (Pubitemid 34913041)
59. Gilmore, W. C. (1991). Drug trafficking by sea: The 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Marine Policy, 15(3), 183-186.
60. Gossop, M., Keaney, F., Sharma, P., & Jackson, M. (2005). The unique role of diamorphine in British medical practice: A survey of general medical practitioners and hospital doctors. European Addiction Research, 11(2), 76-82. (Pubitemid 40529261)
61. Government Services. (1935). Opening of the federal narcotic farm at Lexington, KY. Journal of the American Medical Association, 104(7), 574.
62. GPO. 1970). Controlled Substances Act: 21 USC 812.Washington, DC: U.S. Government Printing Office.
63. Green, T. C., Heimer, R.,&Grau,G. E. (2008).Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction, 103(6), 979-989. (Pubitemid 351703471)
64. Griffith, J. D., Rowan-Szal, G. A., Roark, R. R., & Simpson, D. D. (2000). Contingency management in outpatient methadone treatment: A meta-analysis.Drug and Alcohol Dependence, 58(1-2), 55-66.
65. Gueye, P. N., Megarbane, B., Borron, S. W., Adnet, F., Galliot-Guilley, M., Ricordel, I., et al. (2002). Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99.Addiction, 97(10), 1295-1304.
66. Hartel, D. (1990). Cocaine use, inadequate methadone dose increase risk of AIDS for IV drug users in treatment. NIDA Notes, 5(1), 16-17.
67. Hartel, D., Schoenbaum, E. E., Selwyn, P. A., Friedland, G. H., Feingold, A. R., Alerman, M. H., et al. (1989, June). Temporal patterns of cocaine use and AIDS in intravenous drug users in methadone maintenance. Proceedings of the 5th international conference on AIDS, Stockholm, Sweden.
68. Hartel, D., Selwyn, P. A., Schoenbaum, E. E., Friedland, G. H., Feingold, A. R., Alerman,M. H., et al. (1988, June). Methadone maintenance treatment and reduced risk of AIDS and AIDSspecific mortality in intravenous drug users. Proceedings of the 4th international conference on AIDS, Stockholm, Sweden.
69. Haubrich,W. S. (2003). Medical meanings: A glossary of word origins (2nd ed.). Philadelphia, PA: American College of Physicians.
70. Hawkins, J. (1937). Opium: Addicts and addictions. Danville, VA: J.T. Townes.
71. Higgins S. T., Silverman, K., & Heil, S. H. (Eds.). (2008). Contingency management in substance abuse treatment. New York: Guilford Press.
72. Hser, Y. I., Anglin, M. D., Grella, C., Longshore, D., & Prendergast, M. L. (1997). Drug treatment careers: A conceptual framework and existing research findings. Journal of Substance Abuse Treatment, 14(6), 543-558. (Pubitemid 28053044)
73. Hser, Y. I., Longshore, D., & Anglin, M. D. (2007). The life course perspective on continuing care for substance abuse treatment: A conceptual framework for understanding drug use trajectories. Evaluation Review: A Journal of Applied Social Research, 31(6), 515-547.
74. Hunt, D. (1992, March 19). Methadone clinic shut in raid here. Houston Chronicle, p. 1A.
75. Hyashi, K.,Wood, E.,Wiebe, L., Qi, J.,&Kerr, T. (2010). An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. International Journal of Drug Policy, 21(5), 418-421.
76. Institute of Medicine (2006). Improving the Quality of Health Care for Mental and Substance-Use Disorders: Quality Chasm Series. Washington, DC: National Academy Press.
77. Jaffe, J. H. (2000). Substance-related disorders: Introduction and overview. In B. J. Sadock & M. D. Sadock (Eds.), Comprehensive textbook of psychiatry (7th ed., pp. 924-952). Philadelphia, PA: Lippincott Williams & Wilkins.
78. JAMA. (1935). Narcotic farms: A public policy. Journal of the American Medical Association, 104(4), 566.
79. Johnson, J. A., Knudsen, H., & Roman, P. (2002). Counselor turnover in private facilities. Frontlines: Linking Alcohol Services Research & Practice, November, pp. 5,8.
80. Kahan, M., Wilson, L., Liu, E., Borsoi, D., Brewster, J. M., Sobell, L. C., et al. (2004). Family medicine residents' beliefs, attitudes and performance with problem drinkers: A survey and simulated patient study. Substance Abuse, 25(1), 43-51. (Pubitemid 38480258)
81. Kerr, T., Small, W., Peeace, W., Douglas, D., Pierre, A., & Wood, E. (2006). Harm reduction by a 'user-run' organization: A case study of the Vancouver Area Network of Drug Users (VANDU). International Journal of Drug Policy, 17(2), 61-69. (Pubitemid 43384098)
82. Kieffer, B. L., & Evans, C. J. (2002). Opioid tolerance: In search of the holy grail. Cell, 108(5), 587-590. (Pubitemid 34241419)
83. Kim, D., Irwin, K. S.,&Khoshnood, K. (2009). Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. American Journal of Public Health, 99(3), 402-407.
84. Kleber, H. D. (2008). Methadone maintenance 4 decades later: Thousands of lives saved but still controversial. Journal of the American Medical Association, 300(19), 2303-2305.
85. Knudson, H. K., Ducharme, L. J.,&Roman, P. M. (2007). Research network involvement and addiction treatment center staff: Counselor attitudes toward buprenorphine. American Journal on Addictions, 16(5), 365-371. (Pubitemid 47450756)
86. Krupitsky, E.M., & Blokhina, E. A. (2010). Long-acting depot formulations of naltrexone for heroin dependence: A review. Current Opinion in Psychiatry, 23(3), 210-214.
87. Krupitsky, E. M.,Masalov, D. V., Didenko, T. Y., Burakov, A.M., Romanova, T. N., Zvartau, E. E., et al. (2001). Prevention of suicide by naltrexone in a recently detoxified heroin addict. European Addiction Research, 7(2), 87-88. (Pubitemid 32662601)
88. Krupitsky, E. M., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extendedrelease naltresxone for opioid dependence: A double-blind, placebo-controlled, multicenter randomised trial. The Lancet, 377, 1506-1513.
89. Krupitsky, E. M., Zvartau, E. E., Masalov, D. V., Tsoi, M. V., Burakov, A. M., Egorova, V. Y., et al. (2004). Naltrexone for heroin dependence treatment in Russia. Journal of Substance Abuse Treatment, 26(4), 285-294. (Pubitemid 38759145)
90. Krupitsky, E. M., Zvartau, E. E., Masalov, D. V., Tsoi, M. V., Burakov, A. M., Egorova, V. Y., et al. (2006). Naltrexone and fluoxetine for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 31(4), 319-328. (Pubitemid 44648649)
91. Lenton, S. R., Dietze, P. M., Degenhardt, L., Darke, S., & Butler, T. G. (2009). Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. Drug and Alcohol Review, 28(6), 583-585.
92. Lewis, J. (1998). In pursuit of the holy grail. Retrieved from http://www.cpdd.vcu.edu/Media/Index/AwardSpeeches/Lewis J. Eddy1998.pdf
93. Lintzeris, N. (2009). Prescription of heroin for the management of heroin dependence: Current status. CNS Drugs, 23(6),463-476.
94. Lobmaier, P., Kornør, H., Kunøe, N., & Bjørndal, A. (2008). Sustained-release naltrexone for opioid dependence. Cochrane Database of Systematic Reviews, 2, Art. No. CD006140. doi: 10.1002/14651858. CD006140.pub2. (Pubitemid 351807436)
95. Loftis, J.M., Matthews, A. M.,&Hauser, P. (2006). Psychiatric and substance use disorders in individuals with hepatitis C: Epidemiology and management. Drugs, 66(2), 155-174. (Pubitemid 43213901)
96. Lowry, J. (1956). The hospital treatment of the narcotic addict. Federal Probation, 15, 42-51.
97. Marlatt, G. A. (1998). Highlights of harm reduction. In G. A. Marlatt (Ed.), Harm reduction: Pragmatic strategies for managing high-risk behaviors (pp. 3-29). New York: Guilford Press.
98. Marsh, J. C., Oviedo-Joekes, E., Perea-Milla, E., Carrasco, F., & PEPSA Team. (2006). Controlled trial of prescribed heroin in the treatment of opioid addiction. Journal of Substance Abuse Treatment, 31(2), 203-211. (Pubitemid 44223911)
99. Marshall, E. (1911, March 12). Uncle Sam is the worst drug fiend in the world. New York Times, p. SM12.
100. Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, 3, Art. No. CD002209. doi: 10.1002/14651858.CD002209.pub2.
101. Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, Art. No. CD002207. doi: 10.1002/14651858.CD002207.pub3. (Pubitemid 351807246)
102. Mayet, S., Farrell, M., Ferri, M., Amato, L., & Davoli, M. (2005). Psychosocial treatment for opiate abuse and dependence. Cochrane Database of Systematic Reviews, 1, Art. No. CD004330. doi: 10.1002/14651858.CD004330.pub2.
103. McIntosh, C.,&Ritson, B. (2001). Treating depression complicated by substance misuse. Advances in Psychiatric Treatment, 7(5), 357-364. (Pubitemid 32927163)
104. McKeganey, N. (2008). Should heroin be prescribed to misusers? No. British Medical Journal, 336(7635), 71.
105. McLellan, A. T., Carise, D., & Kleber, H. D. (2003). Can the national addiction treatment infrastructure support the public's demand for quality care? Journal of Substance Abuse Treatment, 25, 117-121. (Pubitemid 37415291)
106. McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association, 284(13), 1689-1695.
107. McLellan, A. T., & Meyers, K. (2004). Contemporary addiction treatment: A review of systems problems for adults and adolescents. Biological Psychiatry, 56(10), 764-770. (Pubitemid 39539834)
108. McNulty, T. L., Oser, C. B., Johnson, J. A., Knudsen, H. K., & Roman, P. M. (2007). Counselor turnover in substance abuse treatment centers: An organizational-level analysis. Sociological Inquiry, 77(2), 166-193.
109. Metrebian, N., Carnwath, T., Stimson, G., & Storz, T. (2002). Survey of doctors prescribing diamorphine (heroin) to opiatedependent drug users in the United Kingdom. Addiction, 97(9), 1155-1161.
110. Metzger, D. S.,Woody, G. E.,McLellan, A. T., O'Brien, C. P., Druley, P., Navaline, H., et al. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and outof-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 6(9), 1049-1056. (Pubitemid 23239778)
111. Meyers, R. J., Miller, W. R., Hill, D. E., & Toniga, J. S. (1998). Community reinforcement and family training (CRAFT): Engaging unmotivated drug users in treatment. Journal of Substance Abuse, 10(3), 291-308. (Pubitemid 128433411)
112. Meyers, R. J., & Smith, J. E. (1995). Clinical guide to alcohol treatment: The community reinforcement approach. New York: Guilford Press.
113. Musto, D. F. (1987a). The history of legislative control over opium, cocaine, and their derivatives. In R.Homowy (Ed.), Dealing with drugs: Consequences of government control (pp. 37-50). San Francisco, CA: Pacific Research Institute for Public Policy.
114. Musto, D. F. (1987b). The American disease: Origins of narcotic control (3rd ed.). New York: Oxford University Press.
115. Musto, D. F. (1991). Opium, cocaine, and marijuana in American history. Scientific American, 265(1), 40-47.
116. Nahra, T. A., Alexander, J., & Pollack, H. (2009). Influence of ownership on access in outpatient substance abuse treatment. Journal of Substance Abuse Treatment, 36, 355-365.
117. Narcotics Anonymous World Services. (2009). NA World Services, Inc., annual report: 1 July 2008-30 June 2009. Van Nuys, CA:
118. Author . NIDA. (2009). Principles of drug addiction treatment: A research based guide (2nd ed.). Bethesda, MD: National Institute on Drug Abuse.
119. NIDA. (2010). NIDA/SAMHSA blending initiative. Retrieved from http://www.nida.nih.gov/Blending/index.html
120. Needle, R. H., & Zhao, L. (2010). HIV prevention among injection drug users: A report of the CSIS Global Health Policy Center. Washington, DC: CSIS.
121. Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Lauzon, P., Guh, D., Anis, A., et al. (2009). Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine, 361, 777-786.
122. Payte, J. T., & Khuri, E. T. (1993). Principles of methadone dose determination. In M. W. Parrino (Ed.), State methadone treatment guidelines (pp. 47-58). Bethesda, MD: Center for Substance Abuse Treatment.
123. Prendergast, M., Podus, D., Finney, J., Greenwell, L., & Roll, J. (2006). Contingencymanagement for treatment of substance use disorders: A meta-analysis. Addiction, 101(11), 1546-1560. (Pubitemid 44527186)
124. Preston, K. L., Silverman, K., Umbricht, A., DeJesus, A., Montoya, I. D.,&Schuster, C. R. (1999). Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence, 54, 127-135. (Pubitemid 29114991)
125. Preston, K. L., Umbricht, A., & Epstein, D. H. (2000). Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Archives of General Psychiatry, 57(4), 395-404. (Pubitemid 30202331)
126. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 264(19), 2511-2518.
127. Rehm, J., & Fischer, B. (2008). Should heroin be prescribed to misusers? Yes. British Medical Journal, 336(7635), 70.
128. Resnick, R. B. (1998). A practitioner's experience with naltrexone. Proceedings of the 29th annual scientific conference of the American Society of Addiction Medicine, New Orleans, L.A.
129. Rettig, R. A., & Yarmolinsky, A. (Eds.). (1995). Federal regulation of methadone treatment. Washington DC: National Academy Press.
130. Rexed, B., Edmondson, D., Khan, I., & Samsom, R. J. (1984). Guidelines for the control of narcotic and psychotropic substances in the context of the international treaties. Geneva: World Health Organization.
131. Robinson v. California, 370 US 660 (Supreme Court, 1962). Rush, B. R., Powell, L. Y., Crowe, T. G., & Ellis, K. (1995). Early intervention for alcohol use: Family physicians' motivations and perceived barriers. Canadian Medical Association Journal, 152(6), 863-869.
132. Salamina, G., Diecidue, R., Vigna-Taglianti, F., Jarre, P., Schifano, P., Bargagli, A. M., et al. (2010). Effectiveness of therapies for heroin addiction in retaining patients in treatment: Results from the Vedette study. Substance Use &Misuse, 45(12), 2076-2092.
133. Serẗurner, F.W. A. (1806). Darstellung der reinenMohns̈aure (Opiums ̈aure), nebst einer chemischen Untersuchung des Opiums [Description of pure poppy acid: Opium acid and an analysis of opium]. Journal of Pharmacology, 14, 47-93.
134. Sevarino, K. A., & Kosten, T. R. (2009). Naltrexone for initiation and maintenance of opiate abstinence. In R. Dean, E. J. Bilsky & S. S. Negus (Eds.), Opiate receptors and antagonists: From bench to clinic (pp. 227-245). New York: Humana.
135. Shapiro, R. S. (1994). Legal bases for the control of analgesic drugs. Journal of Pain and Symptom Management, 9(3), 153-159. (Pubitemid 24134446)
136. Silverman, K.,Wong, C. J.,Higgins, S. T., Brooner, R. K.,Montoya, I. D., Contoreggi, C., et al. (1996). Increasing opiate abstinence through voucher-based reinforcement therapy. Drug and Alcohol Dependence, 41, 157-165. (Pubitemid 26183908)
137. Sloan, F. (2005). Not for profit ownership and hospital behavior. In A. J. Cuyler & J. P. Newhouse (Eds.), Handbook of health economics (Vol. 1, pp. 1141-1174). Amsterdam: Elsevier Science BV.
138. Smith, J. E., Meyers, R. J., & Miller, W. R. (2010). The community reinforcement approach to the treatment of substance use disorders. American Journal on Addictions, 10(s1), s51-s59.
139. Smith, P. (2009a, February 13). Europe: Danish heroin maintenance program to commence next month. Drug War Chronicle, 572. Retrieved from http://stopthedrugwar.org/chronicle/2009/feb/13/europe danish heroin maintenance
140. Smith, P. (2009b, June 5). Europe: German parliament approves heroin maintenance. Drug War Chronicle, 588. Retrieved from http://stopthedrugwar.org/ chronicle/2009/jun/05/europe german parliament approve
141. Solomon, L. M. (2002). The resilient sector: The state of nonprofit America. In L. M. Solomon (Ed.), The state of nonprofit America (pp. 3-61). Washington, DC: Brookings Institution Press.
142. Stimson, G. V., & Metrebian, N. (2003). Prescribing heroin: What is the evidence? London: Rowntree Foundation.
143. Strang, J., & Gossop, M. (2005). Heroin addiction and the British system. New York: Routledge.
144. Strang, J., Manning, V., Mayet, S., Best, D., Titherington, E., Santana, L., et al. (2008). Overdose training and take-home naloxone for opiate users: Prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction, 103(10), 1648-1657.
145. Subramaniam, G. A., Fishman, M. J., & Woody, G. (2009). Treatment of opioid-dependent adolescents and young adults with buprenorphine. Current Psychiatry Reports, 11(5), 360-363.
146. Substance Abuse and Mental Health Services Administration. (2008). National survey of substance abuse treatment services (N-SSATS): 2007. Data on substance abuse treatment facilities. Rockville, MD: SAMHSA/Office of Applied Studies.
147. Substance Abuse and Mental Health Services Administration. (2010). The national survey of substance abuse treatment services (N-SSATS) report: Free substance abuse treatment. Rockville, MD: SAMHSA/Office of Applied Studies.
148. Sullivan, M. A., Vosburg, S. K., & Comer, S. D. (2006). Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology, 189(1), 37-46. (Pubitemid 44607258)
149. Terry, C. E., & Pellens, M. (1928). The opium problem. New York: Bureau of Social Hygiene.
150. Teruya, C., Thomas, C., Rosensteel, A., Hasson, A., Hillhouse, M., Hser, Y., et al. (2010, June). START study retention: Perspectives of suboxone dropouts. Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Scottsdale, A.Z.
151. UNAIDS (The Joint United Nations Programme on HIV/AIDS). 2006). Report on the global AIDS epidemic. Geneva: UNAIDS. Retrieved from http://www.unaids.org/ en/Knowledge Centre/HIVData/GlobalReport/2006/
152. United Nations. (1961). Single convention on narcotic drugs, 1961. Retrieved from http://www.unodc.org/pdf/convention 1961 en.pdf
153. United Nations. (1971). Convention on psychotropic substances, 1971. Retrieved from http://www.incb.org/pdf/e/conv/convention 1971 en.pdf
154. United Nations. (1988). United Nations convention against illicit traffic in narcotic drugs and psychotropic substances. Retrieved from http://www.unodc.org/pdf/convention 1988 en.pdf
155. United Nations International Drug Control Program. (2000). Bulletin on narcotics. New York: United Nations.
156. UNODC (United Nations Office on Drug Control Policy). (2007). 2007 World drug report. Geneva: UNODC.
157. UNODC. (2010). Treatnet. Retrieved from http://www.unodc.org/treatment/ index.html
158. U.S. Census Bureau. (2004). The AIDS pandemic in the 21st century: International population reports. Washington, DC: U.S. Government Printing Office.
159. Van Den Brink, W., Hendriks, V. M., Blanken, P., Koeter, M. W. J., van Zwieten, B. J., & van Ree, J. M. (2003). Medical prescription of heroin to treatment resistant heroin addicts: Two randomized controlled trials. BMJ, 327(7410), 310.
160. Verthein, U., Bonorden-Kleij, K., Degkwitz, P., Dilg, C., K̈ohler,W. K., Passie, T., et al. (2008). Long-term effects of heroin-assisted treatment in Germany. Addiction, 103(6), 960-966. (Pubitemid 351703473)
161. Volkow, N.D.,&Li, T. K. (2004).Drug addiction: The neurobiology of behaviour gone awry. Nature Reviews Neuroscience, 5(12), 963-970. (Pubitemid 39593359)
162. Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55(5), 569-580. (Pubitemid 24192243)
163. White, W. L. (1998). Slaying the dragon: The history of addiction treatment and recovery in America.Normal, IL: Chestnut Health Systems.
164. White, W. L. (2002). Trick or treat? A century of American responses to heroin addiction. In D. Musto (Ed.), One hundred years of heroin. Westport, CT: Auburn House.
165. WHO(World Health Organization). (2003).WHOexpert committee on drug dependence. WHO Technical Report Series. Geneva: Author.
166. WHO. (2004). Neuroscience of psychoactive substance use and dependence. Geneva: Author.
167. WHO. (2005a). Indonesia (Summary country profile for HIV/AIDS treatment scale-up). Retrieved from http://www. who.int/hiv/HIVCP IDN.pdf
168. WHO. (2005b). World Health Organization overview of Malaysia: Injecting drug use and HIV/AIDS. Kunming: Author.
169. WHO. (2008). The methadone fix. Bulletin of the World Health Organization, 86(3), 164-165.
170. WHO. 2009a). Country office for Viet Nam: 2009 year in review. Retrieved from http://www.wpro.who.int/NR/rdonlyres/DC0 0105B-9993-4A9C-8BA4-B587697C043A/ 0/Year In Review 2009 FINAL.pdf
171. Williams, J. T., Christie, M. J., & Manzoni, O. (2001). Cellular and synaptic adaptations mediating opioid dependence. Physiological Reviews, 81(1), 299-343. (Pubitemid 32096178)
172. Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., et al. (2008). Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. Journal of the American Medical Association, 300(17), 2003-2011.
173. Wright, C. R. A. (1874). On the action of organic acids and their anhydrides on the natural alkaloids. Journal of the Chemical Society, 27, 1031-1043.
174. Wu, E., El-Bassel, N., Gilbert, L., Chang, M., & Sanders, G. (2010). Effects of receiving additional off-site services on abstinence from illicit drug use among men on methadone: A longitudinal study. Evaluation and Program Planning, 33(4), 403-409.
175. Zanis, D. A., & Woody G. E. (1998). One year mortality rates following methadone treatment discharge. Drug and Alcohol Dependence, 52(3), 257-260. (Pubitemid 28529584)